Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - Royalty Pharma ( NASDAQ:RPRX ) , Geron ( NASDAQ:GERN )
RYTELO™ ( imetelstat ) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia Transaction increases Royalty Pharma's synthetic royalty funding to $925 million in 2024, highlighting the significant opportunity for this ...
| Ticker |
Sentiment |
Impact |
|
RPRX
|
Somewhat Bullish
|
38 %
|
|
ABBV
|
Neutral
|
4 %
|
|
GERN
|
Neutral
|
18 %
|
